Equities

Mayne Pharma Group Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mayne Pharma Group Ltd

Actions
  • Price (EUR)1.32
  • Today's Change-0.01 / -0.75%
  • Shares traded8.00k
  • 1 Year change-69.16%
  • Beta0.6726
Data delayed at least 15 minutes, as of Mar 03 2026 20:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others. Its subsidiaries include Mayne Pharma International Pty Ltd, Mayne Holdings US Inc, Mayne Pharma LLC, and others.

  • Revenue in AUD (TTM)410.85m
  • Net income in AUD-82.21m
  • Incorporated2005
  • Employees450.00
  • Location
    Mayne Pharma Group Ltd1538 Main North Road, Salisbury SouthADELAIDE 5106AustraliaAUS
  • Phone+61 88209-2666
  • Fax+61 88281-0284
  • Websitehttps://www.maynepharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.